Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00084136 · ClinicalTrials.gov registry record · Phase 4
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
A Phase 4 study, sponsored by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,571
- Enrollment target
NCT00084136 is a Phase 4 study that has completed, run by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections. The registered enrollment target is 1,571 participants.
The verdict
NCT00084136, a Phase 4 study, has completed, sponsored by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,571 participants
- Enrollment target
Study Summary
This study compared 3 different three-drug combinations in HIV infected individuals starting their first HIV treatment regimens. Participants were recruited from resource-limited areas in Africa, Asia, South America, Haiti, and also from the United States. The study hypothesis was each of the once daily combinations (PI based, or NNRTI based) would not have inferior efficacy compared to the twice daily NNRTI based combination.
Interventions
- DRUG Atazanavir
- DRUG Efavirenz
- DRUG Emtricitabine
- DRUG Emtricitabine/Tenofovir disoproxil fumarate
- DRUG Didanosine (enteric-coated)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,571 participants |
| Start Date | 2005-05 |
| Est. Completion | 2010-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00084136
The ClinicalTrials.gov registry entry for NCT00084136 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 1,571 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Atazanavir is the first listed.
NCT00084136 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00084136 about?
NCT00084136 is a clinical study titled "Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings". This study compared 3 different three-drug combinations in HIV infected individuals starting their first HIV treatment regimens. Participants were recruited from resource-limited areas in Africa, Asia, South America, Haiti, and also from the United States. The study hypothesis was each of the once d...
What is the current status of trial NCT00084136?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,571 participants. The study started on 2005-05. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00084136?
The interventions under investigation include: Atazanavir (DRUG), Efavirenz (DRUG), Emtricitabine (DRUG), Emtricitabine/Tenofovir disoproxil fumarate (DRUG), Didanosine (enteric-coated) (DRUG).
Who is sponsoring clinical trial NCT00084136?
This trial is sponsored by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.